Research
Hormonal
Tirzepatide (10-15 mg weekly) produces significantly greater total weight loss (-20.2%) compared to Semaglutide (1.7-2.4 mg weekly, -13.7%) in obese patients, as demonstrated in the SURMOUNT-5 trial.
If you are struggling with obesity and other medications have failed, Tirzepatide (10-15 mg weekly) offers superior weight loss compared to Semaglutide. Discuss this dual-agonist option with your doctor, especially if you have not achieved sufficient weight loss with other GLP-1 treatments.
WeakSupportsHIGH confidence
In the SURMOUNT-5 interventional study, tirzepatide 10 mg/15 mg was significantly superior to semaglutide 1.7 mg/2.4 mg (% total weight loss, TWL: –20.2% vs. –13.7%).
Why this rating
Based on a Phase-III RCT (SURMOUNT-5) with 751 participants.
Source
Pharmakologische und phytotherapeutische Strategien in der integrativen Adipositastherapie
Peter Panhofer et al. · Deutsche Zeitschrift für Akupunktur · 2026
DOI 10.1007/s42212-025-00797-8
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- State-of-the-art anti-obesity medications (AOMs) like GLP-1 analogues are highly effective appetite suppressants but require continuous use, as discontinuation leads to inevitable weight regain.Limited
- Phytotherapeutic agents (e.g., Green Tea, Nigella Sativa, Bofu Tsusho San) produce statistically significant but clinically less relevant weight loss compared to modern AOMs.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →